APP
ATRA icon

Alpha Paradigm Partners’s Atara Biotherapeutics ATRA Stock Holding History

Alpha Paradigm Partners’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,919
Closed -$1.52M – 531
2021
Q2 		$1.52M Buy
+3,919
New +$1.4M 0.57% 31

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Alpha Paradigm Partners's ATRA Position: Q3 2021 in Review

Alpha Paradigm Partners sold out of Atara Biotherapeutics (ATRA) in Q3 2021, closing a stake of 3,919 shares — an estimated $1.52M sold.

Alpha Paradigm Partners first reported a position in ATRA in Q2 2021 and held it in 1 quarter. The position peaked at $1.52M in Q2 2021. 140 funds tracked by Wall St. Rank hold ATRA as of Q3 2021.

  • Alpha Paradigm Partners reported no remaining Atara Biotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Alpha Paradigm Partners sold 3,919 Atara Biotherapeutics shares in Q3 2021, an estimated $1.52M.
  • Alpha Paradigm Partners first reported a position in Atara Biotherapeutics in Q2 2021 and held it in 1 quarter.
  • Alpha Paradigm Partners's Atara Biotherapeutics position peaked at $1.52M in Q2 2021.
  • 140 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2021.

Based on Alpha Paradigm Partners's 13F filing for Q3 2021, filed 15 Nov 2021.